Treatment with Rapamycin in Animal Models of Traumatic Brain Injuries; a Systematic Review and Meta-Analysis
Archives of Academic Emergency Medicine,
Vol. 12 No. 1 (2024),
1 January 2024
,
Page e16
https://doi.org/10.22037/aaem.v12i1.2150
Abstract
Introduction: In light of the potential of enhanced functional and neurological recovery in traumatic brain injury (TBI) with the administration of rapamycin, this systematic review and meta-analysis aimed to investigate the efficacy of rapamycin treatment in animal models of TBI.
Methods: An extensive search was conducted in the electronic databases of Medline, Embase, Scopus, and Web of Science by July 1st, 2023. Two independent researchers performed the screening process by reviewing the titles and abstracts and the full texts of the relevant articles, including those meeting the inclusion criteria. Apoptosis rate, inflammation, locomotion, and neurological status were assessed as outcomes. A standardized mean difference (SMD) with a 95% confidence interval (95%CI) was calculated for each experiment, and a pooled effect size was reported. Statistical analyses were performed using STATA 17.0 software.
Results: Twelve articles were deemed eligible for inclusion in this meta-analysis. Pooled data analysis indicated notable reductions in the number of apoptotic cells (SMD for Tunnel-positive cells = -1.60; 95%CI: -2.21, -0.99, p<0.001), p-mTOR (SMD=-1.41; 95%CI: -2.03, -0.80, p<0.001), and p-S6 (SMD=-2.27; 95%CI: -3.03, -1.50, p<0.001) in TBI post-treatment. Our analysis also indicated substantial IL-1β reductions after rapamycin administration (SMD= -1.91; 95%CI: -2.61, -1.21, p<0.001). Moreover, pooled data analysis found significant neurological severity score (NSS) improvements at 24 hours (SMD= -1.16; 95%CI: -1.69, -0.62, p<0.001; I²=0.00%), 72 hours (SMD= -1.44; 95%CI: -2.00, -0.88, p<0.001; I²=0.00%), and 168 hours post-TBI (SMD= -1.56; 95%CI: -2.44, -0.68, p<0.001; I²=63.37%). No such improvement was observed in the grip test.
Conclusion: Low to moderate-level evidence demonstrated a significant decrease in apoptotic and inflammatory markers and improved neurological status in rodents with TBI. However, no such improvements were observed in locomotion recovery.
- Traumatic Brain Injury (TBI)
- Rapamycin
- Systematic Review
- Meta-analysis
- Animal model
How to Cite
References
Maas AI, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. The Lancet Neurology. 2017;16(12):987-1048.
Zarei H, Vazirizadeh-Mahabadi M, Ramawad HA, Sarveazad A, Yousefifard M. Prognostic value of CRASH and IMPACT models for predicting mortality and unfavorable outcome in traumatic brain injury; a systematic review and meta-analysis. Archives of academic emergency medicine. 2023;11(1).
Majdan M, Plancikova D, Brazinova A, Rusnak M, Nieboer D, Feigin V, et al. Epidemiology of traumatic brain injuries in Europe: a cross-sectional analysis. The Lancet Public Health. 2016;1(2):e76-e83.
Majdan M, Plancikova D, Maas A, Polinder S, Feigin V, Theadom A, et al. Years of life lost due to traumatic brain injury in Europe: a cross-sectional analysis of 16 countries. PLoS medicine. 2017;14(7):e1002331.
Rauen K, Reichelt L, Probst P, Schäpers B, Müller F, Jahn K, et al. Quality of life up to 10 years after traumatic brain injury: a cross-sectional analysis. Health and quality of life outcomes. 2020;18:1-12.
MacFarlane MP, Glenn TC. Neurochemical cascade of concussion. Brain injury. 2015;29(2):139-53.
Kaur P, Sharma S. Recent advances in pathophysiology of traumatic brain injury. Current neuropharmacology. 2018;16(8):1224-38.
Wu J, Lipinski MM. Autophagy in neurotrauma: good, bad, or dysregulated. Cells. 2019;8(7):693.
Dailah HG. Potential of therapeutic small molecules in apoptosis regulation in the treatment of neurodegenerative diseases: An updated review. Molecules. 2022;27(21):7207.
Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2014;84(2):275-91.
Nikolaeva I, Crowell B, Valenziano J, Meaney D, D'Arcangelo G. Beneficial effects of early mTORC1 inhibition after traumatic brain injury. Journal of Neurotrauma. 2016;33(2):183-93.
Wahane SD, Hellbach N, Prentzell MT, Weise SC, Vezzali R, Kreutz C, et al. PI3K‐p110‐alpha‐subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC 2. Journal of neurochemistry. 2014;130(2):255-67.
Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. Control of dendritic arborization by the phosphoinositide-3′-kinase–Akt–mammalian target of rapamycin pathway. Journal of Neuroscience. 2005;25(49):11300-12.
Patt S, Brodhun M. Neuropathological sequelae of traumatic injury in the brain. An overview. Experimental and Toxicologic Pathology. 1999;51(2):119-23.
Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature medicine. 2002;8(2):128-35.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International journal of surgery. 2021;88:105906.
Hooijmans CR, Rovers MM, De Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC medical research methodology. 2014;14:1-9.
Wei D, Tang K, Wang Q, Estill J, Yao L, Wang X, et al. The use of GRADE approach in systematic reviews of animal studies. Journal of Evidence‐Based Medicine. 2016;9(2):98-104.
Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiology of disease. 2007;26(1):86-93.
Park J, Zhang J, Qiu J, Zhu X, Degterev A, Lo EH, et al. Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. Journal of Cerebral Blood Flow & Metabolism. 2012;32(2):330-40.
Guo D, Zeng L, Brody DL, Wong M. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PloS one. 2013;8(5):e64078.
Zhu X, Park J, Golinski J, Qiu J, Khuman J, Lee CC, et al. Role of Akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice. Journal of Cerebral Blood Flow & Metabolism. 2014;34(9):1531-9.
Ding K, Wang H, Wu Y, Zhang L, Xu J, Li T, et al. Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis. Journal of Surgical Research. 2015;194(1):239-47.
Song Q, Xie D, Pan S, Xu W. Rapamycin protects neurons from brain contusion‑induced inflammatory reaction via modulation of microglial activation. Molecular Medicine Reports. 2015;12(5):7203-10.
Wang C, Hu Z, Zou Y, Xiang M, Jiang Y, Botchway BO, et al. The post‐therapeutic effect of rapamycin in mild traumatic brain‐injured rats ensuing in the upregulation of autophagy and mitophagy. Cell biology international. 2017;41(9):1039-47.
Chen Y, Meng J, Xu Q, Long T, Bi F, Chang C, et al. Rapamycin improves the neuroprotection effect of inhibition of NLRP3 inflammasome activation after TBI. Brain Research. 2019;1710:163-72.
Gao C, Yan Yn, Chen G, Wang T, Luo C, Zhang M, et al. Autophagy activation represses pyroptosis through the IL-13 and JAK1/STAT1 pathways in a mouse model of moderate traumatic brain injury. ACS Chemical Neuroscience. 2020;11(24):4231-9.
Campolo M, Casili G, Lanza M, Filippone A, Cordaro M, Ardizzone A, et al. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury. Journal of Cellular and Molecular Medicine. 2021;25(16):7855-66.
Shi Y, Zhou X, Yang R, Ying S, Wang L. Panax notoginseng protects the rat brain function from traumatic brain injury by inhibiting autophagy via mammalian targeting of rapamycin. Aging (Albany NY). 2021;13(8):11207.
Jiang H, Wang Y, Liang X, Xing X, Xu X, Zhou C. Toll-like receptor 4 knockdown attenuates brain damage and neuroinflammation after traumatic brain injury via inhibiting neuronal autophagy and astrocyte activation. Cellular and molecular neurobiology. 2018;38:1009-19.
Clark RS, Kochanek PM, Chen M, Watkins SC, Marion DW, Chen J, et al. Increases in Bcl‐2 and cleavage of caspase‐1 and caspase‐3 in human brain after head injury. The FASEB Journal. 1999;13(8):813-21.
Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RS. Bench-to-bedside review: Apoptosis/programmed cell death triggered by traumatic brain injury. Critical care. 2004;9:1-10.
Clark RS, Kochanek PM, Watkins SC, Chen M, Dixon CE, Seidberg NA, et al. Caspase‐3 mediated neuronal death after traumatic brain injury in rats. Journal of neurochemistry. 2000;74(2):740-53.
Raghupathi R, Fernandez SC, Murai H, Trusko SP, Scott RW, Nishioka WK, et al. BCL-2 overexpression attenuates cortical cell loss after traumatic brain injury in transgenic mice. Journal of Cerebral Blood Flow & Metabolism. 1998;18(11):1259-69.
Xia D, Li W, Qian H, Yao S, Liu J, Qi X. Ischemia preconditioning is neuroprotective in a rat cerebral ischemic injury model through autophagy activation and apoptosis inhibition. Brazilian Journal of Medical and Biological Research. 2013;46:580-8.
Kim YC, Guan K-L. mTOR: a pharmacologic target for autophagy regulation. The Journal of clinical investigation. 2015;125(1):25-32.
Ciechomska I, Goemans G, Skepper J, Tolkovsky A. Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene. 2009;28(21):2128-41.
Nezis IP, Stenmark H. p62 at the interface of autophagy, oxidative stress signaling, and cancer. Antioxidants & redox signaling. 2012;17(5):786-93.
Zhang L, Wang H. Autophagy in traumatic brain injury: a new target for therapeutic intervention. Frontiers in molecular neuroscience. 2018;11:190.
Kang R, Zeh H, Lotze M, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death & Differentiation. 2011;18(4):571-80.
Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. Journal of chemical biology. 2008;1(1):27-36.
Rothwell NJ. Cytokines–killers in the brain? The Journal of Physiology. 1999;514(Pt 1):3.
Ramilo O, Sáez-Llorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ, et al. Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. The Journal of experimental medicine. 1990;172(2):497-507.
Kim K, Wass C, Cross A, Opal S. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine and cytokine research. 1992;11(6):293-8.
Smith R, Giannoudis PV. Trauma and the immune response. Journal of the Royal Society of Medicine. 1998;91(8):417-20.
Ziebell JM, Morganti-Kossmann MC. Involvement of pro-and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics. 2010;7(1):22-30.
Winter CD, Iannotti F, Pringle AK, Trikkas C, Clough GF, Church MK. A microdialysis method for the recovery of IL-1β, IL-6 and nerve growth factor from human brain in vivo. Journal of neuroscience methods. 2002;119(1):45-50.
Jiang P, Guo Y, Dang R, Yang M, Liao D, Li H, et al. Salvianolic acid B protects against lipopolysaccharide-induced behavioral deficits and neuroinflammatory response: involvement of autophagy and NLRP3 inflammasome. Journal of Neuroinflammation. 2017;14(1):1-10.
- Abstract Viewed: 255 times
- pdf Downloaded: 951 times